AZNAstraZenecaRunning, no new patients
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 119 (final count)
- Started
- Jul 11, 2022
- Main results expected
- Nov 7, 2023
- Fully finished
- Jun 30, 2027
- Results posted
- Jun 13, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)
Measured over: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05460273 · record last updated 2026-08-31 · checked 2026-11-09 15:47 UTC